Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
FDA Approves IND for Phase II Studies of TASQ
August 27th, 2007
The review of Active Biotech's IND (Investigational New Drug) for the TASQ prostate cancer project has been completed by the US Food and Drug Administration (FDA). A Phase II proof of concept trial in prostate cancer patients will now be initiated, and the first patients in this trial will start treatment before the end of 2007. The approved trial is a randomized, placebo controlled, double-blind Phase II trial investigating 1 mg/day of TASQ (ABR-215050) versus placebo in 200 patients. The trial will be performed in asymptomatic patients with metastatic, castrate resistant, prostate cancer. This is a similar patient population as that previously...
Source: Clinical Trials Week (2007-08-27)
|
